Cytonics raises $4.8M from crowd of investors for osteoarthritis biologic

What's the deal? CytonicsDealroom has a profile for this one. Try Dealroom →, a clinical-stage biotechnology company developing A2M-based therapies for osteoarthritis, has completed a financing campaign that generated $4.8 million in gross proceeds. The round drew roughly 1,500 investments, including about 900 new investors, and 35% of existing shareholders reinvested.

What's the endgame? The money supports CYT-108, an investigational engineered alpha-2-macroglobulin (A2M) biologic designed to inhibit proteases involved in cartilage degradation. Cytonics has completed a first-in-human Phase 1 study and is preparing a Phase 1b/2a trial in knee osteoarthritis.

The company now counts about 8,000 investors on its cap table and has raised $47 million to date, including $27 million through Regulation A and Regulation Crowdfunding offerings.

Why now? The raise funds regulatory, manufacturing, and clinical planning ahead of the next study. Cytonics has already received more than $4.32 million in non-binding indications of interest for a potential future campaign, which it expects to weigh once additional efficacy data arrive.

The signal: Cytonics is testing whether a shareholder-driven model can bankroll drug development typically funded by institutions. "Biotechnology is usually financed by a small circle of institutions. We have built Cytonics differently," said chief executive officer Joey Bose. The bet: a broad retail base can carry a biologic toward late-stage trials without the usual venture backing.

Image credit: Cytonics